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Objectives
To investigate the inﬂuence of low-dose sildenaﬁl, a
phosphodiesterase type 5 inhibitor (PDE5-I), on the function
of the mouse lower urinary tract (LUT).
Materials and Methods
Adult male mice were decerebrated and arterially perfused with
a carbogenated Ringer’s solution to establish the decerebrate
arterially perfused mouse (DAPM). To allow distinction
between central neural and peripheral actions of sildenaﬁl,
experiments were conducted in both the DAPM and in a
‘pithed’ DAPM, which has no functional brainstem or spinal
cord. The action of systemic and intrathecal sildenaﬁl on
micturition was assessed in urethane-anaesthetised mice.
Results
In the DAPM, systemic perfusion of sildenaﬁl (30 pM)
decreased the voiding threshold pressure [to a mean (SEM)
84.7 (3.8)% of control] and increased bladder compliance [to
a mean (SEM) 140.2 (8.3)% of control, an effect replicated in
the pithed DAPM]. Sildenaﬁl was without effect on most
voiding variables but signiﬁcantly increased the number of
bursts of the external urethral sphincter (EUS) per void in
DAPM [to a mean (SEM) 130.1 (6.9)% of control at 30 pM]
and in urethane-anaesthetised mice [to a mean (SEM)
117.5 (5.8)% of control at 14 ng/kg]. Sildenaﬁl (10 and
30 pM) increased pelvic afferent activity during both bladder
ﬁlling and the isovolumetric phase [to a mean (SEM)
205.4 (30.2)% of control at 30 pM]. Intrathecal application of
sildenaﬁl (5 lL of either 150 pM or 1.5 nM) did not alter
cystometry and EUS-electromyography variables in urethane-
anaesthetised mice.
Conclusions
Low-dose sildenaﬁl increases bladder compliance, increases
pelvic nerve afferent activity, and augments the bursting
activity of the EUS. We propose that the novel actions on
afferent trafﬁc and sphincter control may contribute to its
beneﬁcial actions to restore storage and voiding efﬁciency in
LUT dysfunction.
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Introduction
Phosphodiesterases (PDEs) are enzymes that inactivate the
second messenger molecules cyclic adenosine monophosphate
and cyclic guanosine monophosphate (cGMP). Selective PDE
type 5 inhibitors (PDE5-Is) increase cGMP levels by slowing
its degradation, increasing nitric oxide (NO) production in
peripheral tissues [1]. PDE5-Is are widely used to treat
erectile dysfunction and are increasingly used clinically to
treat LUTS [2]. Several clinical studies have shown that
PDE5-Is improve male LUTS, including both storage and
voiding symptoms, without the impairment of sexual function
seen with other BPH/LUTS treatments [3–7]. However, none
of these studies showed an improvement in peak urinary ﬂow
rate, leaving open the question of how they act to improve
LUTS [3,4,8].
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Studies in rodents and humans suggested that PDE5
inhibition may inﬂuence several mechanisms implicated in
the pathology of BPH/LUTS, including relaxation of detrusor
smooth muscle [9], suppression of bladder afferent activity
[10], reduced prostatic stromal cell proliferation [11], and an
anti-inﬂammatory action on the prostate [12]. However, the
effects of PDE5-Is on the motor control of the lower urinary
tract (LUT) have not been determined. This is of interest as
PDE5 is found in the CNS, including the grey matter of the
lumbosacral spinal cord [13].
The present study aimed to investigate in detail the inﬂuence
of the PDE5-I sildenaﬁl on the function and control of the
mouse LUT. To help achieve this aim, without the
confounding effects of anaesthesia, we employed a recently
described in situ mouse model, the decerebrate arterially
perfused mouse (DAPM) [14]. This has many of the
advantages of accessibility afforded by in vitro approaches but
retains functional neural connectivity. Using this approach,
we found that low-dose sildenaﬁl exerts speciﬁc actions:
increasing bladder compliance, increasing pelvic nerve
afferent activity, and augmenting bursting activity of the
external urethral sphincter (EUS). We propose these latter
novel actions may underlie some of its beneﬁcial actions in
LUT dysfunction.
Materials and Methods
All experiments conformed to the UK Home Ofﬁce guidelines
and were approved by our Institutional Ethical Review
Committee. Male CD1 mice (n = 77; 17 DAPM, 34 pithed
DAPM, 20 in vivo and six in vitro experiments) were used in
these experiments.
In situ DAPM Preparation
For the DAPM preparation [14], the mouse was deeply
anaesthetised with isoﬂurane (2–3%) and the stomach and
intestine were vascularly isolated and removed through a
midline laparotomy. The ureters were cut bilaterally and
ligated distally to prevent bladder ﬁlling. Next the mouse was
cooled by immersion into modiﬁed Ringer’s solution (5–6 °C
on ice, composition below). After craniotomy, the mouse was
decerebrated by aspiration, at the pre-collicular level and
anaesthesia was discontinued. The preparation was skinned
and then pinned to a dissecting dish on ice. The left phrenic
nerve was freed from connective tissues and the lungs and
diaphragm removed.
The preparation was moved to a recording chamber and a
ﬂushed double-lumen cannula (diameter 1.2 mm, ArgyleTM;
Covidien Ltd., Dublin, Republic of Ireland) was inserted into
the ascending aorta via the left ventricle. The right atrium
and inferior vena cava were incised to prevent venous
hypertension during arterial perfusion. The preparation was
perfused with carbogen-gassed Ringer’s containing an osmotic
agent, Ficoll-70 (1.25%; Sigma Aldrich, St. Louis, MO, USA).
The heated perfusate (31 °C) was pumped (15–20 mL/min,
Watson-Marlow pump 505D; Watson-Marlow Ltd.,
Falmouth, Cornwall, UK) from a reservoir ﬂask and was
recycled from the recording chamber back to the reservoir.
Aortic perfusion pressure was monitored via the second
lumen of the cannula. A glass suction electrode was used to
record the left phrenic nerve activity, which was AC ampliﬁed
(5–10 k), band pass ﬁltered (100 Hz–3 kHz), and digitised at
10 kHz.
LUT Recordings
The pubic symphysis was cut in the midline to allow access
to the EUS. A glass suction electrode (tip diameter ~200 lm)
was placed on the proximal sphincter, slightly lateral to the
midline and directly below the bladder neck to record EUS-
electromyography (EMG). A 27-G needle was inserted into
the bladder dome and connected via saline-ﬁlled tubing and a
three-way tap to a pressure transducer and a syringe pump
(GenieTouchTM; Kent Scientiﬁc Corp., Torrington, CT, USA)
for pressure monitoring and infusion of 0.9% saline,
respectively. The standard infusion rate of saline into the
bladder was 25 lL/min in the DAPM, as used in previous
mouse urodynamic studies in vivo [15]. The following
micturition variables were measured (averaged over at least
three voiding cycles):
• Basal pressure was taken as the lowest bladder pressure
reached after a void.
• Voiding threshold was the bladder pressure when the EUS-
EMG started bursting, indicating the initiation of voiding.
• Micturition pressure was the absolute value of peak bladder
pressure achieved during voiding (bursting phase of the
EUS-EMG).
• Non-voiding contractions (NVCs) were identiﬁed as
discrete increases in bladder pressure (>1 mmHg) seen
during the ﬁlling phase in voiding preparations.
• In preparations without voiding (i.e., pithed DAPM), the
small rhythmical pressure ﬂuctuations with an amplitude
> 0.4 mmHg were termed putative micromotions.
• Bladder compliance was deﬁned as bladder capacity/
(threshold – basal pressure) (lL/DmmHg) during ﬁlling at
a rate of 25 lL/min.
Systemic Administration of Sildenaﬁl in DAPM
The effect of sildenaﬁl on bladder and urethral function was
analysed in DAPM. The bladder was ﬁlled at 25 lL/min and
once a stable pattern of micturition was established, baseline
cystometric variables were measured (after more than four
micturition cycles). After obtaining baseline recordings of
voiding cycles, sildenaﬁl was added to the circulating
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perfusate with a cumulative dose every four voiding cycles
(10 and 30 pM).
Distinguishing Central and Peripheral Actions of
Sildenaﬁl in the DAPM
To investigate the peripheral effects of sildenaﬁl on the
bladder (and to exclude any drug effects on CNS), the DAPM
was established and then the cord transected at the medullo-
spinal junction to remove the brain stem; the spinal cord was
then pithed with a blunt wire. The effectiveness of this
procedure was conﬁrmed by a loss of phrenic nerve activity
and of respiratory/pinch-evoked movements. As expected,
without central control, the micturition cycle was lost and the
bladder became overﬂow incontinent. The urethra was
clamped to allow measures of ﬁlling pressure and compliance.
Saline was infused into the bladder (25 lL/min) to a
maximum intravesical pressure of 15 mmHg, to avoid over-
distension. After baseline control ﬁlls, sildenaﬁl was added to
the perfusate and the ﬁlling cycle was repeated.
The Effects of Sildenaﬁl on Pelvic Afferent Nerve
Activity
The pithed DAPM was set up with a polyethylene catheter
(PE-50; Clay-Adams, Parsippany, NJ, USA) sutured into the
dome of bladder. The pelvic nerve was identiﬁed, cut and
recordings were made from the distal end with a bipolar glass
suction electrode. Bladder distention-induced pelvic nerve
activity increased exponentially over the normal range of
pressures seen during the micturition cycle (<15 mmHg).
Nerve activity was AC ampliﬁed (5–10 k), band pass ﬁltered
(100 Hz–3 kHz), and digitised at 10 kHz. Multiﬁbre afferent
nerve activity was quantiﬁed by thresholding to count the
number of action potentials (Spike2; Cambridge Electronic
Design [CED], Cambridge, UK). The threshold level for spike
counting was set at the peak level of the smallest identiﬁable
spikes in the baseline pelvic nerve recording (i.e., with an
empty bladder). After clamping the urethra, saline was
infused (25 lL/min) until the intravesical pressure reached
15 mmHg (ﬁlling phase) and then the infusion was stopped
for 3 min (isovolumetric phase). At the end of each cycle, the
bladder was emptied by aspiration.
The Effects of Systemic and Intrathecal Sildenaﬁl
in vivo
Sildenaﬁl was administered either intraperitoneally (i.p.) or
intrathecally to urethane-anaesthetised mice (1.0–1.2 mg/g,
i.p.) to investigate its systemic and spinal actions on the
LUT. For EUS-EMG recordings, stainless steel insulated
wires (0.075 mm diameter) were inserted into the
sphincter muscle percutaneously. The bladder was
cannulated with a PE-50 catheter (Clay-Adams) to
monitor intravesical pressure.
Systemic sildenaﬁl at doses of 4.67, 14 and 140 ng/kg was
made up to 50 lL with saline before i.p. administration
(estimated ﬁnal concentration of 10, 30 and 300 pM in body
ﬂuid, assumed to be distributed in total body water, i.e., 70% of
the mouse body weight). For intrathecal access, the L4–L6
vertebral spines were exposed through a midline skin incision.
Sildenaﬁl (5 lL of 150 pM) was applied intrathecally, assuming
the intrathecal cerebrospinal ﬂuid volume was 20 lL, this
resulted in an estimated ﬁnal intrathecal concentration of
30 pM. Likewise, for a ﬁnal intrathecal concentration of
300 pM we injected 5 lL of 1.5 nM sildenaﬁl. Lidocaine (5 lL,
1%) was injected at the end of experiment to conﬁrm
intrathecal targeting by prompt cessation of voiding (n = 3).
Electrical Field Stimulation (EFS)-Induced
Contractions of EUS in vitro
Mice were killed by cervical dislocation and the whole
bladder outﬂow tract was removed through a midline
laparotomy. The preparation (10 mm length, 3 mm diameter,
containing urethral smooth muscle and the EUS) was tied to
an isometric force transducer in a perfusion trough, and
superfused with Ringer’s solution at 37 °C. Nerve-mediated
tetanic contractions were generated by EFS (0.1 ms pulses,
40 Hz, 3-s train). The peak force of contractions and area
under the curve (AUC) were normalised for tissue
preparation weight (mN/g). After sildenaﬁl (10 and 30 pM)
application, sodium nitroprusside (SNP, 100 lM) was
administrated as a positive control [16] and EFS repeated.
Drugs and Solutions
The composition of Ringer’s was (in mM): NaCl (125),
NaHCO3 (24), KCl (3.0), CaCl2 (2.5), MgSO4 (1.25), KH2PO4
(1.25); Glucose (10); pH 7.35–7.4 with 95% O2/5% CO2.
Ficoll-70 (1.25%) was added as an oncotic agent to the
perfusate. Stock solutions of sildenaﬁl (750 lM) and SNP
(340 mM) were made in distilled water and kept frozen until
the experiment, at which time they were diluted in Ringer’s
and perfused at the ﬁnal concentrations. All salts and drugs
were from Sigma.
Data Acquisition
Perfusion pressure, phrenic nerve activity, electrocardiogram,
bladder pressure, pelvic nerve and EUS-EMG activity were
recorded using custom-built AC ampliﬁers and transducers
(built by Mr Jeff Croker, University of Bristol, Bristol, UK),
and digitised using a micro1401 A–D interface (CED) to a
computer running Spike2 software (version 7, CED).
Analysis
Analysis was conducted ofﬂine, using Spike2 software and the
Statistical Package for Social Sciences (SPSS), version 22
© 2019 The Authors
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(SPSS Inc., Chicago, IL, USA). The distribution of the
sampled variables was assessed using the Shapiro–Wilk
normality test. Statistical testing was by repeated measures
ANOVA with parametric (t-test) or non-parametric (Mann–
Whitney U-test) tests as appropriate. All values are expressed
as the mean (SEM) or median (interquartile range),
Table 1 Cystometry and perfusion pressure in DAPM before and after sildenaﬁl.
Variable Sildenaﬁl (n = 6), mean (SEM) Vehicle control (n = 6), mean (SEM)
Baseline After sildenaﬁl 10 pM After
sildenaﬁl 30 pM
Baseline After vehicle 1 After vehicle 2
Basal pressure mmHg 6.6 (0.7) 6.3 (0.8) 6.3 (0.8) 6.7 (0.4) 6.5 (0.4) 6.4 (0.4)
Threshold pressure, mmHg 14.5 (1.4) 13.2 (1.4) 12.4 (1.6)* 14.6 (1.3) 14.3 (1.2) 14.5 (1.3)
Micturition pressure, mmHg 23.1 (2.4) 22.1 (2.1) 23.4 (2.5) 22.6 (1.9) 23.0 (1.9) 23.1 (1.8)
Infused volume, lL 100.4 (12.5) 92.5 (7.7) 98.6 (8.4) 99.8 (10.8) 100.6 (8.9) 90.1 (5.8)
Inter-void interval, s 241.1 (30.1) 221.9 (18.5) 236.7 (20.2) 239.6 (26.0) 241.1 (21.5) 237.6 (31.6)
Bladder compliance, lL/DmmHg 14.5 (3.4) 16.3 (3.9) 19.7 (4.0)* 14.3 (2.7) 14.4 (2.2) 14.1 (2.7)
Number of NVCs in 1 min 1.5 (0.7) 1.4 (0.5) 1.2 (0.4) 1.4 (0.3) 1.5 (0.3) 1.1 (0.3)
Average amplitude of NVC, mmHg 3.2 (0.7) 3.3 (0.4) 3.3 (0.4) 3.0 (0.7) 2.5 (0.4) 2.7 (0.4)
Perfusion pressure, mmHg 68.9 (4.3) 67.6 (3.9) 67.9 (4.5) 66.2 (3.0) 67.3 (3.0) 68.2 (2.7)
*P < 0.05, signiﬁcant difference from baseline, repeated-measures ANOVA with Dunnett’s test for multiple comparison.
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Fig. 1 Sildenaﬁl increases bladder compliance, reduces voiding threshold and increases EUS bursting. (A) Representative recordings of bladder
pressure and EUS-EMG activity in the DAPM before and after administration of sildenaﬁl (10 and 30 pM) to the perfusate. (B) Sildenaﬁl signiﬁcantly
decreased the threshold pressure (P = 0.029) and increased bladder compliance (P = 0.011). Sildenaﬁl signiﬁcantly increased the number of bursts of
EUS-EMG activity per void compared with baseline (P = 0.023) and vehicle control recordings (at 30 pM, P = 0.033). Repeated measures ANOVA with
Dunnett’s test for multiple comparison. *P < 0.05 compared to baseline; #P < 0.05 compared to vehicle, unpaired t-test.
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n = number of preparations. The null hypothesis was rejected
at P < 0.05.
Results
Effects of Sildenaﬁl on the Micturition Cycle and
Urethral Sphincter Control in DAPM
Systemic administration of sildenaﬁl signiﬁcantly reduced
perfusion pressure at 100 pM in DAPM [to a mean (SEM)
85.8 (0.7)% of baseline, n = 5; P < 0.001, paired t-test].
Because perfusion pressure was monitored in the aorta in the
DAPM (with maintained constant ﬂow from the perfusion
pump), this indicated that the 100 pM dose of sildenaﬁl was
having a substantial biological effect to lower the vascular
resistance. Therefore, to avoid this confounding consequence,
sildenaﬁl was used at 10 and 30 pM in DAPM, which did not
reduce perfusion pressure. The effect of sildenaﬁl on
cystometric variables of the storage and voiding phases in
DAPM was assessed (n = 6, Table 1). At 30 pM
concentration, sildenaﬁl decreased the threshold pressure [to
a mean (SEM) 84.7 (3.8)% of control, P = 0.029] and increased
bladder compliance [to a mean (SEM) 140.2 (8.3)%, P = 0.011;
Fig. 1A,B]. The number of bursts of EUS-EMG activity per
void compared with baseline was also signiﬁcantly increased
[to a mean (SEM) 130.1 (6.9)% of control, P = 0.023;
Table 2]). Sildenaﬁl at 10 pM, as well as vehicle (saline)
controls, had no signiﬁcant effects on these measures
(Tables 1 and 2).
Direct Relaxant Action of Sildenaﬁl on the Bladder
To test for a direct action of sildenaﬁl on bladder function,
the DAPM was pithed to ablate central neural control. With
a ﬁll to a vesical pressure of 15 mmHg, sildenaﬁl (30 pM)
Table 2 EUS-EMG variables in DAPM before and after sildenaﬁl.
Variable Vehicle control (n = 6), mean (SEM) Sildenaﬁl (n = 6), mean (SEM)
Before After vehicle 1 After vehicle 2 Before After sildenaﬁl 10 pM After sildenaﬁl 30 pM
Number of spike bursts in each void 23.4 (3.2) 20.1 (1.7) 19.6 (2.0) 20.4 (1.3) 23.4 (1.7) 26.4 (2.0)*,†
Spike frequency within burst, Hz 4.7 (0.3) 5.0 (0.7) 4.6 (0.7) 4.7 (0.7) 4.6 (0.7) 4.6 (0.7)
*P < 0.05 signiﬁcant difference from before sildenaﬁl administration, the repeated-measures Dunnett’s test for multiple comparison. †P < 0.05 signiﬁcant difference from vehicle of
sildenaﬁl, unpaired t-test.
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Fig. 2 Peripheral actions of sildenaﬁl. (A) Recordings of bladder pressure changes in response to saline infusion were made in the pithed DAPM. (B)
Administration of sildenaﬁl (30 pM) to the perfusate increased bladder compliance, which led to a consequent increase in the volume infused before
the maximum pressure threshold was reached (15 mmHg). Repeated-measures ANOVA with Dunnett’s test for multiple comparisons *P < 0.05: difference
from baseline.
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signiﬁcantly increased bladder capacity [to a mean (SEM)
112.5 (3.3)% of control, P = 0.036] and increased bladder
compliance [to a mean (SEM) 111.9 (3.4)% of control,
P = 0.035] compared with baseline (n = 8). Sildenaﬁl at
10 pM had no signiﬁcant effects (Fig. 2A,B, Table S1).
Sildenaﬁl Augments Bladder Afferent Nerve Activity
Recordings were made from the pelvic nerve in the pithed
DAPM to test for an action of sildenaﬁl on bladder primary
afferent terminals [14]. Under control conditions, intravesical
saline infusion evoked an increase in pelvic afferent activity
that ramped up with the increase of pressure [mean (SEM)
ﬁring rate 0.25 (0.1) Hz at 0 mmHg and 16.8 (3.0) Hz at
15 mmHg, n = 18 preparations). With a maintained bladder
volume at 15 mmHg [mean (SEM) 80.8 (9.2) lL, n = 18],
there was a partial reduction of afferent ﬁring to a mean
(SEM) of 11.0 (2.2) Hz (n = 18). Sildenaﬁl, at both 10 and
30 pM, signiﬁcantly increased pelvic afferent activity during
ﬁlling when referenced against both bladder pressure
(Fig. 3A,Bi) and bladder volume (Fig. S1A) at doses of both
10 and 30 pM; compared with the baseline values and also
against vehicle controls (Fig. 3Bii and Fig. S1B). Sildenaﬁl at
30 pM also signiﬁcantly increased pelvic afferent activity
during the isovolumetric phase [to a mean (SEM)
205.4 (30.2)% of control at 30 pM, P = 0.002; Fig. 3Ci,ii].
Vehicle treatment was without effect on the pelvic afferent
activity (Fig. 3Ci,ii).
Systemic Sildenaﬁl Increases EUS-EMG Bursting
Activity per Void in vivo
Systemic application of sildenaﬁl (4.67, 14 and 140 ng/kg)
signiﬁcantly increased the number of bursts of EUS-EMG
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Fig. 3 Sildenaﬁl increases bladder afferent activity. (A) Pelvic nerve recording of afferent activity showed a ramping increase with bladder ﬁlling and this
declined to a plateau during an isovolumetric storage phase. Sildenaﬁl (10 and 30 pM) augmented afferent activity during both phases. (Bi) Sildenaﬁl
(10 and 30 pM) increased pelvic afferent activity during the ﬁlling phase referenced against bladder pressure. (Bii) Proportionate change in afferent
ﬁring across bladder pressures caused by sildenaﬁl compared to vehicle control, in each case normalised to the baseline bladder ﬁll-evoked activity.
(Ci) Sildenaﬁl (10 and 30 pM) signiﬁcantly increased pelvic afferent activity even after stopping saline infusion into the bladder and losing the dynamic
component of bladder wall stretch (P = 0.002), and standardised values of afferent ﬁring rate by baseline showed signiﬁcant difference compared to
vehicle group (Cii). *P < 0.05, **P < 0.01 difference from baseline, related-samples Friedman’s one-way ANOVA by ranks. #P < 0.05, ##P < 0.01 difference
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activity per void compared with baseline [to a mean (SEM)
117.5 (5.8)% of control at 14 ng/kg, P = 0.008], as well as in
comparison with vehicle control recordings (P = 0.038;
Table 3, Fig. 4A,B). Cystometry showed no signiﬁcant
changes after systemic application of sildenaﬁl (Table 4).
Intrathecal application of sildenaﬁl (5 lL of 150 pM and
1.5 nM) produced no signiﬁcant change in mouse cystometry
(Table 5) or EUS-EMG variables (Table 6).
Table 3 EUS-EMG variables in urethane-anaesthetised mice before and after systemic sildenaﬁl administration.
Variable Systemic administration of vehicle (N = 7), mean
(SEM)
Systemic administration of sildenaﬁl (N = 7), mean (SEM)
Before After
vehicle 1
After
vehicle 2
After
vehicle 3
Before After
sildenaﬁl 10 pM
After
sildenaﬁl 30 pM
After
sildenaﬁl 300 pM
Number of spike
bursts in each
void
21.8 (4.8) 22.3 (3.2) 22.1 (4.5) 22.1 (2.8) 23.0 (2.7) 25.2 (3.7) 27.0 (3.3) 27.1 (2.7)
Spike frequency
within burst, Hz
6.8 (0.3) 7.1 (0.4) 7.1 (0.3) 7.1 (0.4) 7.0 (0.4) 6.9 (0.2) 7.1 (0.3) 7.2 (0.2)
Bladder pressure
(mmHg)
EMG
(μV)
-600
600
0
20
1 min 2 s
EMG
(μV)
-600
600
0
A Baseline
Sildenafil (30 pM)
Bladder pressure
(mmHg)
EMG
(μV)
-600
600
0
20 EMG
(μV)
-600
600
0
1 s
400mg
Administration of Sildenafil
(10 pM)
Administration of Sildenafil
(30 pM)
Baseline
Administration of SNP 
(100μM)
C Maximum amplitude of contraction Area under curve
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Fig. 4 Sildenaﬁl increases EUS bursting in vivo, an effect not mediated by altered EUS contractility. (A) Representative recording of bladder pressure and
EUS-EMG activity in urethane-anaesthetised mouse showing systemic (i.p.) administration of sildenaﬁl 14 ng/kg (~30 pM) increasing the number of EUS
bursts. (B) Pooled normalised data showing sildenaﬁl signiﬁcantly increased the EUS-EMG activity during voiding compared to both baseline and to
vehicle group. (C) Representative recording of tetanic contractions of whole EUS induced by EFS after administration of sildenaﬁl (10 and 30 pM) and
the NO donor, SNP (100 lM) to the perfusate. Note that sildenaﬁl had no effect on contractility, whereas it was markedly reduced by SNP. (D) Plots of
maximum amplitude and AUC of EFS-induced contraction showed no change after sildenaﬁl administration (10, 30 and 300 pM), and both were
signiﬁcantly reduced by SNP (100 lM). *P < 0.05, **P < 0.01 difference from baseline, related-samples Friedman one-way ANOVA by ranks. #P < 0.05
difference from vehicle, Mann–Whitney U-test.
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Sildenaﬁl does not Modulate the Contractility of the
EUS in vitro
Sildenaﬁl (10 and 30 pM) did not alter the maximum
amplitude [mean (SEM) 124.5 (28.2) mN/g at baseline] or
AUC [mean (SEM) 424.4 (110.1) mN/g.s at baseline] of the
tetanic EUS contractions generated by EFS (n = 6, Fig. 4C).
By contrast, a positive control experiment with the NO donor
SNP (100 lM) reduced the magnitude and AUC of the tetanic
EUS contraction (by a mean (SEM) of 66.1 (6.3)% and
53.9 (9.1)%, respectively, n = 6, P = 0.014; Fig. 4D).
Discussion
Several mechanisms have been proposed by which PDE5-Is
can improve LUTS including relaxation of the bladder and
prostate smooth muscle, increased peripheral oxygenation,
and decreased afferent activity [2]. However, the precise
mechanism(s) that provide the clinical beneﬁt remain to be
elucidated.
In the present study, systemic sildenaﬁl decreased the
threshold pressure for voiding and increased bladder
compliance, with effects at a relatively low concentration of
30 pM [17]. The effect on bladder compliance was
independent of central neural control, as it was also observed
in the ‘pithed’ DAPM preparation. Previous in vitro organ-
bath studies with rabbit and human detrusor strips showed
sildenaﬁl relaxed detrusor strips at 0.1–1 lM [9,18,19] and
thus were about three orders of magnitude higher than that
used in the present study (10 and 30 pM). Attempts to use
higher systemic doses of sildenaﬁl (≥100 pM) in the DAPM
were compromised by a signiﬁcant fall in vascular resistance
(a known effect of PDE5-Is on vascular smooth muscle)
indicating that the effects reported in the present study were
within a functional systemic range for the drug. Thus, the
observed effects of sildenaﬁl on LUT function at very low
concentrations may be clinically relevant and indicates the
presence of mechanisms that do not rely solely on direct
smooth muscle relaxation.
Systemic (but not intrathecal) sildenaﬁl increased the number
of EUS-EMG bursts in each void without a direct effect on
EUS muscle contractility. These data indicate that the effects
of sildenaﬁl on EUS-EMG bursting arise outside the spinal
cord but not within the sphincter itself. We propose that this
bursting activity is important for efﬁcient voiding in mice
[14] and rats [20,21], and that the increase of bursting will
facilitate voiding. There are no previous studies measuring the
effects of PDE5-Is on the electrical activity of EUS. A
previous immunocytochemical study identiﬁed PDE5
expression in the striated muscle of rat EUS, suggesting that
pelvic striated muscles are possibly regulated by PDE5 [16].
However, the present study did not demonstrate any effect of
sildenaﬁl on the contractile function of isolated mouse EUS
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preparations. In addition, sildenaﬁl has been shown to relax
urethral smooth muscle, but at much higher concentrations
in mouse (0.1–10 lM) [22] and rat (0.1–1 lM) [16] isolated
preparations. Such a relaxant effect of sildenaﬁl using doses
in the low micromolar range does not account for the
increase in sphincter EMG bursting in our present study. We
also note that previous clinical studies in man have not found
PDE5-Is to increase urinary ﬂow rate [3,4,8]. This suggests
that a simple direct relaxant effect on the EUS cannot fully
explain improvement of LUTS by sildenaﬁl.
Direct recordings showed that sildenaﬁl increased mouse
pelvic afferent nerve activity (when assessed against both
bladder pressure and distension, so controlling for the change
in compliance). Several previous studies have reported that
PDE5-Is and NO reduce mechanosensitive afferent activity of
both A d- and C-ﬁbres evoked by bladder distension in the
rat [10,23,24]. However, it is worth noting that these reports
of inhibitory effects of PDE5-Is on bladder afferent discharge
were found at higher bladder pressures (30 cmH2O) than the
voiding threshold in normal rats (about 10–15 cmH2O
[25,26]) possibly reﬂecting inhibitory effects in a noxious
range (i.e., on nociceptors), rather than in the normal range
of storage and threshold pressures. This increase in the
afferent activity may account for the reduction in the
threshold pressure for voiding produced by sildenaﬁl.
We propose that the increased afferent activity produced by
sildenaﬁl in the normal range of micturition pressures and
degrees of bladder distension facilitates better co-ordination
of bladder and sphincter function. This is in contrast to the
previous report that higher doses of sildenaﬁl (1–10 mg/kg)
inhibit afferent transmission, proposed to reduce urgency
[10]. Consistent with our proposal, it is known that EUS
motor neurones can be activated via segmental inputs [27],
and studies in rats [28] and cats [29] showed that electrical
stimulation of pelvic afferents elicited reﬂex ﬁring in
pudendal nerve efferent or the EUS. Thus, the augmented
bladder afferent activity observed in the present study might
increase EUS-EMG bursting observed in mice after sildenaﬁl.
However, this will require further investigation to test this
hypothesis (likely requiring pudendal nerve recording and
assessment in pathophysiological animal models including
spinal cord injury, BOO, and ageing).
Summary
Sildenaﬁl, at picomolar concentrations, increased EUS activity
during voiding, and in addition increased bladder compliance
and decreased threshold pressure for micturition. Sildenaﬁl
increased bladder afferent activity in the normal range of
bladder volumes and pressures, consistent with it increasing
the mechanosensitive feedback from the bladder during the
micturition cycle. We propose that the increased bladder
afferent activity may drive increased EUS activity during
voiding, as previous studies demonstrated links between
bladder afferent activity and pudendal efferent/EUS activity.
This novel ﬁnding, demonstrating increased sphincter EMG
bursting, may provide an alternative mechanism for the
beneﬁcial effects of sildenaﬁl in LUTS. Although sphincter
bursting activity is not believed to be present in humans, the
Table 5 Cystometry in urethane-anaesthetised mice before and after intrathecal sildenaﬁl.
Variable Intrathecal administration of sildenaﬁl (n = 6) , mean (SEM)
Before After sildenaﬁl 30 pM After sildenaﬁl 300 pM
Basal pressure, mmHg 4.7 (0.7) 3.5 (0.3) 3.7 (0.5)
Threshold pressure, mmHg 10.0 (0.8) 8.9 (0.8) 9.2 (0.9)
Micturition pressure, mmHg 20.2 (3.4) 19.0 (3.2) 19.5 (3.1)
Infused volume, lL 96.0 (13.9) 100.0 (13.8) 98.4 (14.5)
Inter-void interval, s 230.3 (33.5) 240.0 (33.2) 236.2 (34.8)
Bladder compliance, lL/DmmHg 19.4 (4.6) 19.1 (1.7) 18.9 (2.9)
Number of NVCs in 1 min 1.5 (0.8) 1.6 (0.5) 2.2 (1.1)
Average amplitude of NVC, mmHg 3.4 (0.8) 2.0 (0.1) 2.1 (0.3)
Table 6 EUS-EMG variables in urethane-anaesthetised mice before and after intrathecal sildenaﬁl administration.
Variable Intrathecal administration of sildenaﬁl (N = 6), mean (SEM)
Before After sildenaﬁl 30 pM After sildenaﬁl 300 pM
Number of spike bursts in each void 26.1 (7.1) 26.6 (7.8) 27.9 (9.6)
Spike frequency within burst, Hz 6.6 (0.3) 6.4 (0.3) 6.2 (0.5)
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increase in pelvic afferent trafﬁc in the non-nociceptive range
may improve LUTS symptoms in a proportion of patients.
Conclusions
Using the DAPM, we have identiﬁed a novel effect of
sildenaﬁl on the EUS and bladder afferents, which may
mediate the clinically useful effects of PDE5-Is in the
treatment of LUTS.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1 Sildenaﬁl increases bladder afferent activity in the
DAPM. (A) Sildenaﬁl (30 pM) increased pelvic afferent activity
during the ﬁlling phase when referenced against bladder
volume. (B) Proportionate change in afferent ﬁring against
bladder volume caused by sildenaﬁl compared to vehicle
control (in each case normalised to the baseline bladder ﬁll-
evoked activity). *P < 0.05: difference from baseline, related-
samples Friedman’s one-way ANOVA by ranks. #P < 0.05,
##P < 0.01: difference from vehicle, Mann–Whitney U-test.
Table S1 Cystometry in pithed DAPM before and after
sildenaﬁl.
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